Maintained by Sreepriya Prasannan

MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist

Compiled from ClinicalTrials.gov and CTIS registry records · Last verified 26 Sep 2026 · Editorial standards

At a glance

Peking University People's Hospital is the lead sponsor of 159 current clinical trials in our China register. 108 are recruiting patients now. The most common phase is Observational. The drugs named most often in its trials are Aldesleukin, All-trans retinoic acid and Car-T. The most-studied condition is Acute Myeloid Leukemia.

ClinicalTrials.gov trials by status

Recruiting10868%
Not yet open3220%
Active, closed159%
By invitation43%

Trials by phase

Observational5635%
Not applicable4428%
Phase 23019%
Phase 1/296%
Phase EARLY_PHASE164%
Phase 153%
Phase 343%
Phase 2/332%
Phase 421%

Clinical trials sponsored by Peking University People's Hospital

159 on ClinicalTrials.gov

Study	Phase	Status	Start	Registers
Cadherin 3(CDH3)-Targeted PET in Lung Malignant Tumors NCT07487883 · Non-Small Cell Lung Cancer, Malignant Neoplasm, Pulmonary Nodules	Observational	Recruiting	2026-03	China
ctDNA-Guided De-Escalation of Adjuvant Chemotherapy With Dalpiciclib in HR-Positive/HER2-Negative Breast Cancer NCT06970912 · ClinicalTrials.gov ↗ · Hormone Receptor-Positive Breast Cancer, High-risk Breast Cancer, Early-Stage Breast Cancer Drug: Dalpiciclib	Phase 2	Recruiting	2025-08	China
CDK4/6 Inhibitors Combined With Endocrine Therapy for Neoadjuvant Treatment NCT07366112 · ClinicalTrials.gov ↗ · Hormone Receptor-Positive Breast Cancer, High-risk Breast Cancer, Early-Stage Breast Cancer	Phase 2	Recruiting	2026-04	China
Apatinib Combined With Liposomal Irinotecan for Refractory or Metastatic Osteosarcoma NCT07479732 · ClinicalTrials.gov ↗ · Osteosarcoma, Osteosarcoma Metastatic Drug: Liposomal Irinotecan	Phase 1/2	Recruiting	2026-03	China
Weight Management in Overweight Endometrial Cancer Patients Undergoing Fertility-sparing Treatment NCT06169449 · ClinicalTrials.gov ↗ · Endometrium Cancer	Not applicable	Recruiting	2022-04	China
To Conduct Multi-omics Integrated Studies in Peripheral Blood, Such as Fragment Omics, Metabolomics and Epigenetics, and Establish Non-invasive Dynamic Follow-up Monitoring Programs During Perioperative and Postoperative Periods (Observational Study) NCT07291921 · ClinicalTrials.gov ↗ · Lung Neoplasms, Neoadjuvant Therapy, Immunotherapy	Observational	Recruiting	2025-05	China
MCB vs EUS-FNA for Preoperative Pathological Evaluation of Gastric SMT NCT06748690 · ClinicalTrials.gov ↗ · Gastrointestinal Stromal Tumor of Stomach, Submucosal Tumor of Stomach	Not applicable	Recruiting	2024-01	China
Coated Aldehyde Oxystarch for Protein-Bound Uremic Toxin Reduction in End-Stage Renal Disease NCT07653711 · ClinicalTrials.gov ↗ · End Stage Renal Disease on Dialysis	Not applicable	Recruiting	2025-04	China
Evaluation of an EpCAM-Targeted Radiotracer in Epithelial Tumors NCT07400263 · ClinicalTrials.gov ↗ · Epithelial Tumors, Malignant	Not applicable	Recruiting	2026-03	China
The Efficacy and Safety of Combined Teriflunomide and High-dose Dexamethasone in Newly Diagnosed Primary Immune Thrombocytopenia (TEMPO-2) NCT07065968 · ClinicalTrials.gov ↗ · Immune Thrombocytopenia (ITP) Drugs: Dexamethasone, Teriflunomide	Phase 2	Recruiting	2025-08	China
Clinical Performance of Urine HPV Testing in Males NCT06671210 · ClinicalTrials.gov ↗ · HPV, Self-sampling, Male	Observational	Recruiting	2024-11	China
Automated Bone Age Estimation From Noncontrast Abdominal CT Using Deep Learning NCT07162168 · ClinicalTrials.gov ↗ · Bone Aging, Osteoporosis Diagnosis	Observational	Recruiting	2024-09	China
Interactions Between Environmental Exposures and Gut Microbiota in Early Life NCT06479928 · ClinicalTrials.gov ↗ · Infant Development	Observational	Recruiting	2023-07	China
Immunomodulatory Therapy and Predictors of Clinical Cure in Chronic Hepatitis B NCT07328711 · ClinicalTrials.gov ↗ · Chronic Hepaititis B	Phase EARLY_PHASE1	Recruiting	2026-01	China
Interferon-α for TP53 Myeloid Malignancy Post Allo-HSCT NCT06130579 · ClinicalTrials.gov ↗ · Myeloid Leukemia, Myelodysplastic Syndromes Drug: IFN-α	Phase 2	Recruiting	2024-01	China
Reduced ATG Plus Mini PTCy for GVHD Prophylaxis in Haplo-SCT NCT06984536 · ClinicalTrials.gov ↗ · Myelodysplastic Syndrome, Acute Leukemia	Phase 2	Recruiting	2025-05	China
Endoscopic and Robotic NSM with Immediate Prosthesis Breast Reconstruction NCT06748677 · ClinicalTrials.gov ↗ · Nipple-sparing Mastectomy, Immediate Prosthesis Reconstruction, Endoscopic Surgery	Observational	Recruiting	2025-01	China
Cardiovascular Outcomes and Risk Evaluation Among Recipients of Hematopoietic Stem Cell Transplantation NCT07349498 · ClinicalTrials.gov ↗ · Hematopoietic Stem Cell Transplantation, Transplant Complication, Cardiovascular Events	Observational	Recruiting	2026-01	China
Ablation Compare With Surgery for Early Breast Cancer NCT07484087 · ClinicalTrials.gov ↗ · Breast Cancer, Early Stage, Hormone Receptor Positive	Not applicable	Recruiting	2026-01	China
Impact of Recombinant Humanized Type III Collagen on the Immediate and Long-term Effects of Breast Tumor Surgery NCT06725082 · ClinicalTrials.gov ↗ · Breast Cancer, Collagen Protein	Phase 1	Recruiting	2024-12	China
Geriatric Assessment (GA) for Elderly Patients Undergoing Allo-HSCT NCT06946654 · ClinicalTrials.gov ↗ · Elderly, Geriatric Assessment, ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION	Observational	Recruiting	2026-01	China
Vitreous Zonule in Primary Angle-Closure Glaucoma NCT07523139 · ClinicalTrials.gov ↗ · Primary Angle-Closure Glaucoma	Observational	Recruiting	2025-01	China
Comprehensive Assessment System for Fallopian Tube Function and Clinical Study on Individualized Treatment Strategies NCT07808229 · ClinicalTrials.gov ↗ · Multidimensional Tubal Function Assessment and Individualized Treatment Strategies for Tubal Factor Infertility	Not applicable	Recruiting	2026-08	China
Fucoidan in the Treatment of Active Rheumatoid Arthritis NCT07045896 · ClinicalTrials.gov ↗ · Arthritis, Rheumatoid	Not applicable	Recruiting	2026-01	China
Thiotepa-Containing Conditioning Regimen for Allogeneic HSCT in Chronic Myelomonocytic Leukemia NCT07588594 · ClinicalTrials.gov ↗ · Chronic Myelomonocytic Leukemia (CMML)	Not applicable	Recruiting	2026-02	China
Fertility-sparing Therapy for Patients With Stage IA Endometrial Cancer NCT05945407 · ClinicalTrials.gov ↗ · Endometrial Neoplasms, Endometrial Neoplasm Malignant, Endometrial Neoplasm Malignant Stage I	Not applicable	Recruiting	2016-08	China
De-escalation of Neoadjuvant Chemotherapy Regimens With Immunotherapy Among TNBC NCT06692725 · ClinicalTrials.gov ↗ · Triple Negative Breast Cancer	Observational	Recruiting	2019-01	China
A Cohort Study of Combined Cryoablation and Thermal Ablation for Non-surgical Treatment of Breast Cancer Patients NCT07238894 · ClinicalTrials.gov ↗ · Ablation, Breast Cancer	Not applicable	Recruiting	2026-03	China
Modality of Adjuvant Radiotherapy and Chemotherapy for Stage Ⅲ Endometrial Cancer NCT04453904 · ClinicalTrials.gov ↗ · Endometrial Cancer	Not applicable	Recruiting	2020-05	China
Clinical Registration Study of Haplo-HSCT for Elderly Patients With Acute Leukemia/ Myelodysplastic Syndrome NCT05902416 · ClinicalTrials.gov ↗ · Acute Leukemia, Myelodysplastic Syndromes	Observational	Recruiting	2023-06	China
Mini-dose MTX Plus Standard-dose Steroid for the Initial Treatment of Acute GVHD NCT05921305 · ClinicalTrials.gov ↗ · Acute Graft Versus Host Disease	Phase 3	Recruiting	2023-08	China
CD19 CAR-T vs DLI for Post-HSCT MRD in Ph- ALL: A RCT NCT07441291 · ClinicalTrials.gov ↗ · B ALL, Allogenetic Hematopoietic Stem Cell Transplantation, MRD-positive Drug: Car-T	Phase 3	Recruiting	2025-11	China
An Open and Dose-escalation Early Clinical Study of CD19 and CD20 CAR-T Cell Therapy for Relapsed or Refractory Aggressive B-cell Lymphoma NCT07344818 · ClinicalTrials.gov ↗ · R/R Aggressive B-cell Lymphoma	Phase EARLY_PHASE1	Recruiting	2026-01	China
Nanobody-Based Anti-CD5 CAR-T for Relapsed/Refractory T-ALL/NHL NCT06874946 · ClinicalTrials.gov ↗ · Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, T - Cell Lymphoma, PTCL	Phase 1/2	Recruiting	2025-02	China
Leukemia Stem Cell-based Assay to Predict Relapse and Survival in Patients With Acute Myeloid Leukemia NCT07537738 · ClinicalTrials.gov ↗ · Acute Myeloid Leukemia (AML), MLL Rearrangement	Observational	Recruiting	2025-06	China
The Efficacy and Safety of Third-generation TKIs Combined With Azacitidine and Bcl-2 Inhibitor in Patients With CML-MBP NCT06390306 · ClinicalTrials.gov ↗ · Chronic Myeloid Leukemia Drugs: Azacitidine, Olverembatinib, Ponatinib	Observational	Recruiting	2024-07	China
To Observe the CD7-targeted CAR-T Therapy in the Treatment of r/r PTCL NCT07143929 · ClinicalTrials.gov ↗ · CD7 Positive R/R PTCL Drug: Car-T	Phase 1	Recruiting	2025-08	China
Prospective Study of Teclistamab in the Treatment of Systemic AL Amyloidosis NCT06699394 · ClinicalTrials.gov ↗ · AL Amyloidosis	Not applicable	Recruiting	2025-03	China
Conditioning Regimen in Elderly AML Patients Receiving Haplo-HSCT. NCT06946602 · ClinicalTrials.gov ↗ · AML, Elderly	Not applicable	Recruiting	2026-01	China
Neoadjuvant Therapy Study Guided by Drug Screening in Vitro for Human Epidermal Growth Factor Receptor 2 (HER2) Negative Early Breast Cancer Patients NCT04836156 · ClinicalTrials.gov ↗ · HER2-negative Early Breast Cancer	Phase 1/2	Recruiting	2021-04	China
Thiotepa Combined With Busulfan and Fludarabine Conditioning Regimen for Haploidentical Hematopoietic Stem Cell Transplantation in Elderly Patients With High-Risk Acute Myeloid Leukemia NCT06869265 · ClinicalTrials.gov ↗ · Acute Myeloid Leukemia (AML), High Risk Acute Myeloid Leukemia(AML), Relapsed/Refractory Acute Myeloid Leukemia (AML)	Phase 2	Recruiting	2025-05	China
Romiplostim N01 Plus ATRA for Persistent Isolated Chemotherapy-Induced Thrombocytopenia After Complete Remission of Gynecologic, Breast, or Lung Solid Tumors NCT07586826 · ClinicalTrials.gov ↗ · Persistent Isolated Chemotherapy-Induced Thrombocytopenia, Chemotherapy-Induced Thrombocytopenia, Gynecologic Cancers Drugs: All-trans retinoic acid, Romiplostim N01	Phase 2	Recruiting	2025-12	China
Clinical Validation of a Pre-trained and Fine-tuned Model for Analyzing Time-Series Electronic Health Records in Critical Care NCT07795450 · ClinicalTrials.gov ↗ · Critical Care Medicine, Mortality Prediction	Observational	Recruiting	2026-01	China
A Novel Conditioning Regimen for Haplo-HSCT in Older Patients With SAA NCT07586735 · ClinicalTrials.gov ↗ · Severe Aplastic Anemia, Aplastic Anaemia, Hematopoietic Cell Transplant	Observational	Recruiting	2026-06	China
Rapid dFLC Response Predict CHR in AL Amyloidosis NCT06627309 · ClinicalTrials.gov ↗ · Systemic AL Amyloidosis	Observational	Recruiting	2024-10	China
Real-world Immuno-therapy in Chinese Newly Diagnosed Multiple Myeloma Patients NCT07296627 · ClinicalTrials.gov ↗ · Newly Diagnosed Multiple Myeloma (NDMM)	Observational	Recruiting	2025-07	China
Decitabine Plus mBU/CY for High Risk Acute Leukemia With MRD Pre-HSCT NCT03793517 · ClinicalTrials.gov ↗ · Stem Cell Transplant Complications, Leukemia, Myeloid, Acute, Leukemia Relapse Drug: Decitabine	Phase 2/3	Recruiting	2018-09	China
IASO207 Injection in the Treatment of Relapsed/Refractory B-cell Malignancies NCT07574346 · ClinicalTrials.gov ↗ · Malignancies	Phase EARLY_PHASE1	Recruiting	2026-05	China
Predictive Value of Myelodysplastic Syndrome Stem Cells Determined by Multiparameter Flow Cytometry NCT06569095 · ClinicalTrials.gov ↗ · Myelodysplastic Syndromes	Observational	Recruiting	2024-12	China
KPD Consolidation After ASCT in NDMM Patients NCT06879379 · ClinicalTrials.gov ↗ · Multiple Myeloma, Newly Diagnosed	Phase 2/3	Recruiting	2025-03	China
Autologous Non-cultured Epidermal Cell Suspension Transplantation in the Treatment of Vitiligo NCT07187882 · ClinicalTrials.gov ↗ · Vitiligo	Not applicable	Recruiting	2024-04	China
Comparative Study on the Effect of Diet Interventions on Weight Loss in Overweight Endometrial Cancer Patients Undergoing Fertility-sparing Treatment NCT07318727 · ClinicalTrials.gov ↗ · Endometrium Cancer	Not applicable	Recruiting	2025-01	China
Allogeneic CAR-T(CT0890B) in NKG2DL+ R/R AML NCT07617285 · ClinicalTrials.gov ↗ · AML, Refractory/Relapse Acute Myeloid Leukemia	Phase 1	Recruiting	2026-05	China
B7-H3 NIR Imaging for Osteosarcoma Surgery NCT06778603 · ClinicalTrials.gov ↗ · Osteosarcoma, Resection Margins, B7-H3 Probe	Phase 1/2	Recruiting	2024-01	China
The Beijing Angle Closure Progression Study NCT05563623 · ClinicalTrials.gov ↗ · Angle-Closure Glaucoma	Observational	Recruiting	2022-08	China
Mechanism of Enhanced Efficacy of Ivonescimab in Neoadjuvant Therapy for Non-Small Cell Lung Cancer NCT07359040 · ClinicalTrials.gov ↗ · Non-Small Cell Lung Cancer, Neoadjuvant Therapy, PD-1 Inhibitors Drug: Ivonescimab	Observational	Recruiting	2025-07	China
Efficacy, Safety and Immunological Evaluation of Upadacitinib for Relapsing Polychondritis NCT06873100 · ClinicalTrials.gov ↗ · Relapsing Polychondritis Drug: Upadacitinib	Phase 1/2	Recruiting	2024-11	China
Second Haplo-transplantation for Graft Failure NCT06512519 · ClinicalTrials.gov ↗ · Graft Failure, Stem Cell Transplant Complications	Not applicable	Recruiting	2024-07	China
Real-world Study of Pyrotinib-containing Regimens of Advanced HER2-positive Breast Cancer NCT07600164 · ClinicalTrials.gov ↗ · HER2 + Breast Cancer, Advanced Breast Cancer Drugs: Pyrotinib, Trastuzumab Rezetecan	Phase 4	Recruiting	2026-07	China
Prediction of Postoperative Treatment Efficacy and Recurrence Risk of High-risk GIST Based on Liquid Biopsy MRD NCT05408897 · ClinicalTrials.gov ↗ · Gastrointestinal Stromal Tumors, Minimal Residual Disease	Observational	Recruiting	2022-01	China
Prospective Evaluation of Dynamic Serum ProGRP for Treatment Response Monitoring in Ewing Sarcoma NCT07725783 · ClinicalTrials.gov ↗ · Ewing Sarcoma	Observational	Recruiting	2025-09	China
Digital PCR of CHIP and MR for MRD Monitoring After Allo-HSCT in AML NCT07500441 · ClinicalTrials.gov ↗ · Acute Myeloid Leukemia (AML)	Observational	Recruiting	2026-03	China
PD-1 Inhibitor Combined With Progesterone Treatment in FST for Patients With MMRd Endometrial Cancer NCT06549855 · ClinicalTrials.gov ↗ · Endometrial Cancer, Endometrioid Carcinoma, Mismatch Repair Deficiency Drug: Sintilimab	Not applicable	Recruiting	2024-09	China
Fertility Sparing Therapy for Patients With Stage IA G2 Endometrial Cancer NCT06468215 · ClinicalTrials.gov ↗ · Carcinoma, Endometrioid, Fertility Preservation	Not applicable	Recruiting	2024-06	China
MRD Response-adapted Allo-HSCT for Adverse-risk AML NCT06301425 · ClinicalTrials.gov ↗ · Acute Myeloid Leukemia	Not applicable	Recruiting	2024-05	China
Sonrotoclax Plus Dexamethasone With or Without Daratumumab Regimen in Patients With t(11;14) Primary AL Amyloidosis NCT07335887 · ClinicalTrials.gov ↗ · AL Amyloidosis (AL), t(11;14) Positive	Phase 2	Recruiting	2026-02	China
Clinical Study of a New Treatment Model for Elderly Lung Cancer Patients NCT07632664 · ClinicalTrials.gov ↗ · Lung Neoplasm, Thoracic Surgical Procedures, Perioperative Care	Not applicable	Recruiting	2024-08	China
Efficacy of pHA130 Hemoadsorption for 4 Hours (p4H Study) NCT07111260 · ClinicalTrials.gov ↗ · End Stage Renal Disease on Dialysis	Not applicable	Recruiting	2025-07	China
Modified Second Haplo-transplantation for Graft Failure NCT06512545 · ClinicalTrials.gov ↗ · Graft Failure, Stem Cell Transplant Complications	Not applicable	Recruiting	2024-07	China
Fluzoparib Combined With Camrelizumab for Neoadjuvant Treatment of Embryogenic BRCA Mutation HER2 Negative Breast Cancer: an Open, Single Arm, Multicenter Study NCT05576389 · ClinicalTrials.gov ↗ · Germline BRCA-mutated HER2-negative Breast Cancer Drugs: Camrelizumab, Fluzoparib	Phase 2	Recruiting	2022-10	China
Romiplostim N01 Plus ATRA for Persistent Isolated Chemotherapy-Induced Thrombocytopenia After Complete Remission of Gastrointestinal Solid Tumors NCT07586813 · ClinicalTrials.gov ↗ · Persistent Isolated Chemotherapy-Induced Thrombocytopenia, Chemotherapy-Induced Thrombocytopenia, Gastrointestinal Neoplasms Drugs: All-trans retinoic acid, Romiplostim N01	Phase 2	Recruiting	2025-12	China
Longitudinal Cohort of Thrombosis and Hemostasis Diseases NCT06727669 · ClinicalTrials.gov ↗ · Immune Thrombocytopenia, Thrombotic Thrombocytopenic Purpura, Hemophilia A, Acquired	Observational	Recruiting	2024-11	China
A RWS of SC MTX in Chinese RA Patients NCT07463937 · ClinicalTrials.gov ↗ · Rheumatoid Arthritis (RA)	Observational	Recruiting	2024-09	China
Efficacy and Safety of Telitacicept in the Treatment of Refractory Rheumatoid Arthritis NCT07796516 · ClinicalTrials.gov ↗ · Difficult-to-treat Rheumatoid Arthritis, Rheumatoid Arthritis Drug: Telitacicept	Phase 2	Recruiting	2026-09	China
Longitudinal Cohort Study on Invasive Fungal Disease After Allogeneic Hematopoietic Stem Cell Transplantation NCT07569055 · ClinicalTrials.gov ↗ · Invasive Fungal Disease, Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)	Observational	Recruiting	2025-03	China
Real-world Study of Aflibercept 8 mg in nAMD NCT07640997 · ClinicalTrials.gov ↗ · Neovascular Age-Related Macular Degeneration (nAMD) Drug: Aflibercept	Observational	Recruiting	2025-11	China
Bridging Allogeneic Hematopoietic Stem Cell Transplantation or Not After CD19 CAR - T (S1904) Cell Therapy for r/r B-cell Acute Lymphoblastic Leukemia NCT06581081 · ClinicalTrials.gov ↗ · Relapsed Adult ALL, B-cell Acute Lymphoblastic Leukemia, Refractory Acute Lymphoblastic Leukemia	Not applicable	Recruiting	2024-10	China
Efficacy and Safety of Avatrombopag in the Treatment of Thrombocytopenia After Haplo-HSCT NCT06202625 · ClinicalTrials.gov ↗ · Thrombocytopenia, Stem Cell Transplant Complications	Phase 2/3	Recruiting	2024-05	China
Kahook Dual Blade Goniotomy in Chronic Primary Angle-Closure Glaucoma NCT07517302 · ClinicalTrials.gov ↗ · Primary Angle-closure Glaucoma	Not applicable	Recruiting	2025-03	China
Interferon-alpha As Maintenance Therapy for Favorable-risk Acute Myeloid Leukemia NCT06802718 · ClinicalTrials.gov ↗ · Acute Myeloid Leukemia Drug: Interferon	Phase 3	Recruiting	2023-01	China
Evaluation of Musculoskeletal Aging and Related Disorders Via Advanced Clinical Imaging NCT07474571 · ClinicalTrials.gov ↗ · Osteoarthitis, Osteoporosis	Observational	Recruiting	2005-11	China
Nanobody-Based CD19/CD22 Tandem Dual CAR-T Therapy for R/R B-ALL NCT06880913 · ClinicalTrials.gov ↗ · Precursor B-Cell Lymphoblastic Leukemia-Lymphoma	Phase 1/2	Recruiting	2024-11	China
Baricitinib for Post-HSCT Persistent Thrombocytopenia NCT07535645 · ClinicalTrials.gov ↗ · Persistent Thrombocytopenia, Allogeneic Hematopoietic Stem Cell Transplantation Drug: Baricitinib	Phase 1/2	Recruiting	2026-03	China
Peripheral Blood Versus Bone Marrow Plus Peripheral Blood Grafts for Haploidentical Transplantation in Severe Aplastic Anemia NCT07629947 · ClinicalTrials.gov ↗ · Severe Aplastic Anemia (SAA)	Not applicable	Recruiting	2026-06	China
Weekly Irinotecan Liposomes in Recurrent or Refractory Ewing Sarcoma NCT06340204 · ClinicalTrials.gov ↗ · Ewing Sarcoma	Phase 1	Recruiting	2024-03	China
To Observe the CD7-targeted CAR-T Therapy in the Treatment of MRD Positive T-ALL/LBL Post Allo-HSCT NCT07280494 · ClinicalTrials.gov ↗ · CD7+ T-ALL/LBL	Phase 1	Recruiting	2025-08	China
Daratumumab, Bortezomib, Cyclophosphamide, and Dexamethasone Therapy for Patients with MIDD NCT06418477 · ClinicalTrials.gov ↗ · Monoclonal Gammopathy of Renal Significance	Phase 2	Recruiting	2024-06	China
FAP-targeted PET/NIR in Lung Malignant Tumors NCT07498933 · ClinicalTrials.gov ↗ · Non-Small Cell Lung Cancer, PET/CT, Neoadjuvant Therapy	Observational	Recruiting	2025-06	China
Patient-derived Tumor-like Cell Clusters Predict Progesterone Sensitivity in Patients With Early Endometrial Cancer NCT05647109 · ClinicalTrials.gov ↗ · Endometrial Carcinoma Stage I, Atypical Endometrial Hyperplasia	Observational	Recruiting	2021-09	China
Risk Stratification and MRD-driven Maintenance for MM After ASCT NCT06697483 · ClinicalTrials.gov ↗ · Multiple Myeloma Drugs: Daratumumab, Lenalidomide	Not applicable	Recruiting	2024-12	China
Neoadjuvant Therapy Study Guided by Drug Screening in Vitro for HER2 Positive Early Breast Cancer Patients NCT04750122 · ClinicalTrials.gov ↗ · HER2-positive Early Breast Cancer	Phase 1/2	Recruiting	2021-03	China
Haplo-HSCT for Myelofibrosis NCT06674382 · ClinicalTrials.gov ↗ · Myelofibrosis	Not applicable	Recruiting	2024-01	China
Progesterone Therapeutic Regimen Plus Statins in Young Women With Early Endometrial Carcinoma and Atypical Endometrial Hyperplasia NCT06102863 · ClinicalTrials.gov ↗ · Atypical Endometrial Hyperplasia and Endometrial Carcinoma Stage I	Phase 2	Recruiting	2023-04	China
Long-Term Outcomes in SLE at Peking University People's Hospital NCT07005479 · ClinicalTrials.gov ↗ · Systemic Lupus Erythematosus	Observational	Recruiting	2020-05	China
A Prediction Model in Pregnant Women With Aplastic Anemia NCT07101770 · ClinicalTrials.gov ↗ · Aplastic Anemia, Pregnancy, Prediction Model	Observational	Recruiting	2025-11	China
Multiomics Tumor Evolution Model of NSCLC NCT05352035 · ClinicalTrials.gov ↗ · Non-small Cell Lung Cancer	Observational	Recruiting	2022-04	China
Light and Anesthesia NCT07517484 · ClinicalTrials.gov ↗ · Light, Anesthesia, Sedation	Not applicable	Recruiting	2025-10	China
The Effect of Exercise-Induced Irisin on Brain Function and Postoperative Delirium in Older Adults NCT07424170 · ClinicalTrials.gov ↗ · Post Operative Delirium	Observational	Recruiting	2026-07	China
Using Multiparametric Flow Cytometry to Detect Peripheral Blood and Bone Marrow Leukaemia Stem Cells for Relapse Prediction in P-AML NCT06452732 · ClinicalTrials.gov ↗ · Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia	Observational	Recruiting	2024-11	China
BCMA-CD19 CAR-T Therapy for Refractory Autoimmune Diseases NCT06794008 · ClinicalTrials.gov ↗ · Systemic Lupus Erythematosus, Inflammatory Myopathy, Systemic Sclerosis (SSc)	Phase 2	Recruiting	2024-12	China

Showing the 100 most recently updated of 159 trials (recruiting first). The rest are in the country registers linked in each row.

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

Drugs in Peking University People's Hospital trials

44 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

+ 4 more in the trial list above.

Conditions in Peking University People's Hospital trials

243 conditions

Acute Myeloid Leukemia5 Myelodysplastic Syndromes5 Osteosarcoma5 Immune Thrombocytopenia (ITP)5 Breast Cancer5 Endometrial Cancer5 Ewing Sarcoma4Stem Cell Transplant Complications4Non-Small Cell Lung Cancer3 Hormone Receptor-Positive Breast Cancer3 Neoadjuvant Therapy3Minimal Residual Disease3Acute Leukemia3 Acute Myeloid Leukemia (AML)3 Immune Thrombocytopenia3 Pulmonary Nodules2 PET/CT2High-risk Breast Cancer2Early-Stage Breast Cancer2 HER2-negative Breast Cancer2Endometrium Cancer2Lung Neoplasms2 Immunotherapy2End Stage Renal Disease on Dialysis2

By trial register

Register	Trials	Recruiting
Clinical trials in China	159	108

A trial with sites in more than one country appears in each of those registers; recruiting counts cover the trials listed on this page.

Other sponsors in Acute Myeloid Leukemia

Sponsor	Trials
The First Affiliated Hospital of Soochow University	14
First Affiliated Hospital of Zhejiang University	6
Taiho Oncology	5
Zhejiang University	5
Shenzhen Geno-Immune Medical Institute	4
Stichting Hemato-Oncologie voor Volwassenen Nederland	3
Orca Biosystems	3
Shanghai Jiao Tong University School of Medicine	3
Kura Oncology	2
Shenzhen University General Hospital	2

Sponsors with the most current trials registered for this condition.

Questions about Peking University People's Hospital trials

How many clinical trials does Peking University People's Hospital sponsor?

Peking University People's Hospital is the lead sponsor of 159 current trials on ClinicalTrials.gov in our China register, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are Peking University People's Hospital trials recruiting?

Yes. 108 of its 159 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is Peking University People's Hospital testing?

Its current trials name 44 drugs and biologicals as interventions. The most frequent are Aldesleukin (2), All-trans retinoic acid (2), Car-T (2), Dexamethasone (2) and IFN-α (2). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, lead sponsor, phase, overall status, start date, conditions and intervention names
EU Clinical Trials Information System (CTIS) ↗ EU trial numbers, titles, sponsor, phase, status, therapeutic area and member-state countries

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.

Peking University People's Hospital clinical trials